Research shows that 1 in 8 adults in the US has used one of the popular GLP-1 medications, most of them trying to manage chronic conditions such as diabetes and heart disease and others to help them lose weight.
But nearly 60% of the people taking these drugs – including Ozempic and Mounjaro for diabetes and Wegovy and Zepbound for obesity – stop treatment before 12 weeks, before the medicines can provide clinically meaningful weight loss, studies also show.
Side effects such as diarrhea, vomiting and nausea can prompt some people to quit the medication. Others stop because they don’t feel like the drugs are working or because of concerns over price. Although manufacturers offer assistance programs, they can cost around $1,000 or more without insurance.
I don’t think that class of drug will be a threat to Vascepa/Vazkepa.
Market Data 
Markets 
AI
